Talking Medicines targets growing demand for GLP-1 patient intelligence

Tern plc

Talking Medicines is using consumer conversations around GLP-1 weight-loss plateaus to show how behavioural data can help life sciences companies better understand patients, treatment expectations and communication needs.

The company’s analysis found that many consumers do not automatically see a weight-loss plateau as treatment failure. Instead, they discuss practical responses such as changing exercise habits, improving hydration and considering dose adjustments. These conversations also show patients actively comparing experiences and seeking advice from others.

Patient behaviour can affect adherence, expectations and the way treatment is perceived over time. For pharmaceutical companies, understanding these shifts can help improve patient education, support programmes and communication strategies.

Talking Medicines describes this trend as informed consumerisation. Patients are becoming more active in treatment decisions and are using online information and peer experiences to shape their views. That creates demand for tools that can capture and interpret what patients are saying outside traditional clinical settings.

The company’s analysis also found that attitudes can change as treatment progresses. Early focus on rapid weight loss may move towards maintenance, tolerance and longer-term lifestyle goals. Consumers also discuss frustration, motivation and uncertainty, showing that emotional responses can influence how they view treatment.

Dose stability, side effects and medication tolerance become more important as treatment continues. These factors can affect whether patients remain engaged and how they respond to medical or commercial messaging.

Talking Medicines’ DrugVoice platform converts unstructured healthcare conversations into behavioural intelligence. The aim is to help life sciences companies understand not only what patients are saying, but why attitudes and behaviours may be changing.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Talking Medicines highlights strategic signals emerging across the GLP-1 consumer market

GLP-1 consumers are increasingly weighing access, affordability, quality, clinical oversight and treatment support, creating new strategic considerations across the wider life sciences market.

Tern Plc launches £509,368 underwritten Open Offer

Tern Plc has announced an underwritten Open Offer to raise approximately £509,368 through the issue of 56.6 million shares at 0.90p each. Qualifying shareholders may subscribe for one new share for every 16 shares held, with the offer closing on 22 September 2026.

Talking Medicines targets a growing data need around GLP-1 treatment journeys

Talking Medicines is using GLP-1 discontinuation conversations to show how DrugVoice can help pharmaceutical companies track changing patient needs across the treatment journey.

Device Authority adopts usage-based pricing to support KeyScaler expansion

Device Authority has moved KeyScaler to usage-based pricing, aiming to reduce licensing friction and support broader adoption of its machine identity security platform.

Talking Medicines targets growing demand for GLP-1 patient intelligence

Talking Medicines is using GLP-1 patient conversations to show how behavioural data can help pharmaceutical companies understand changing treatment expectations and engagement.

Talking Medicines builds its AI strategy around specialist life sciences intelligence

Talking Medicines is positioning specialist healthcare intelligence as the core layer that gives agentic AI useful context in life sciences.

Search